Early Correlation of Microglial Activation with Enhanced Tumor Necrosis Factor-alpha and Monocyte Chemoattractant Protein-1 Expression Specifically Within the Entorhinal Cortex of Triple Transgenic Alzheimer's Disease Mice

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2005 Oct 20

PMID 16232318

Citations 122

Authors

Michelle C Janelsins

Michael A Mastrangelo

Salvatore Oddo

Frank M LaFerla

Howard J Federoff

William J Bowers

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease is a complex neurodegenerative disorder characterized pathologically by a temporal and spatial progression of beta-amyloid (Abeta) deposition, neurofibrillary tangle formation, and synaptic degeneration. Inflammatory processes have been implicated in initiating and/or propagating AD-associated pathology within the brain, as inflammatory cytokine expression and other markers of inflammation are pronounced in individuals with AD pathology. The current study examines whether inflammatory processes are evident early in the disease process in the 3xTg-AD mouse model and if regional differences in inflammatory profiles exist.

Methods: Coronal brain sections were used to identify Abeta in 2, 3, and 6-month 3xTg-AD and non-transgenic control mice. Quantitative real-time RT-PCR was performed on microdissected entorhinal cortex and hippocampus tissue of 2, 3, and 6-month 3xTg-AD and non-transgenic mice. Microglial/macrophage cell numbers were quantified using unbiased stereology in 3xTg-AD and non-transgenic entorhinal cortex and hippocampus containing sections.

Results: We observed human Abeta deposition at 3 months in 3xTg-AD mice which is enhanced by 6 months of age. Interestingly, we observed a 14.8-fold up-regulation of TNF-alpha and 10.8-fold up-regulation of MCP-1 in the entorhinal cortex of 3xTg-AD mice but no change was detected over time in the hippocampus or in either region of non-transgenic mice. Additionally, this increase correlated with a specific increase in F4/80-positive microglia and macrophages in 3xTg-AD entorhinal cortex.

Conclusion: Our data provide evidence for early induction of inflammatory processes in a model that develops amyloid and neurofibrillary tangle pathology. Additionally, our results link inflammatory processes within the entorhinal cortex, which represents one of the earliest AD-affected brain regions.

Citing Articles

A Novel Missense Variant in SORBS2 Is Causative With Familial Alzheimer's Disease.

Wang Q, Wang S, Cao S, Wang Q, Wei Y, Li Y CNS Neurosci Ther. 2025; 31(2):e70256.

PMID: 39912518 PMC: 11800137. DOI: 10.1111/cns.70256.

Endocrine Disrupting Toxicity of Bisphenol A and Its Analogs: Implications in the Neuro-Immune Milieu.

Buoso E, Masi M, Limosani R, Oliviero C, Saeed S, Iulini M J Xenobiot. 2025; 15(1.

PMID: 39846545 PMC: 11755641. DOI: 10.3390/jox15010013.

assessment of neuroinflammatory cytokines in different stages of ovine natural prion disease.

Guijarro I, Garces M, Badiola J, Monzon M Front Vet Sci. 2024; 11:1404770.

PMID: 39493812 PMC: 11528339. DOI: 10.3389/fvets.2024.1404770.

Entorhinal vessel density correlates with phosphorylated tau and TDP-43 pathology.

Llamas Rodriguez J, van der Kouwe A, Oltmer J, Rosenblum E, Mercaldo N, Fischl B Alzheimers Dement. 2024; 20(7):4649-4662.

PMID: 38877668 PMC: 11247684. DOI: 10.1002/alz.13896.

Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice.

Jagadeesan N, Roules G, Chandrashekar D, Yang J, Kolluru S, Sumbria R J Transl Med. 2024; 22(1):291.

PMID: 38500108 PMC: 10946165. DOI: 10.1186/s12967-024-05008-x.

References

Strohmeyer R, Rogers J . Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimers Dis. 2002; 3(1):131-157. DOI: 10.3233/jad-2001-3118. View

Afagh A, Cummings B, Cribbs D, Cotman C, Tenner A . Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol. 1996; 138(1):22-32. DOI: 10.1006/exnr.1996.0043. View

Tuppo E, Arias H . The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2004; 37(2):289-305. DOI: 10.1016/j.biocel.2004.07.009. View

Davies C, Mann D, Sumpter P, YATES P . A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci. 1987; 78(2):151-64. DOI: 10.1016/0022-510x(87)90057-8. View

Hanisch U . Microglia as a source and target of cytokines. Glia. 2002; 40(2):140-155. DOI: 10.1002/glia.10161. View

Vehmas A, Kawas C, Stewart W, Troncoso J . Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2002; 24(2):321-31. DOI: 10.1016/s0197-4580(02)00090-8. View

Koenigsknecht-Talboo J, Landreth G . Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005; 25(36):8240-9. PMC: 6725530. DOI: 10.1523/JNEUROSCI.1808-05.2005. View

Nestor P, Scheltens P, Hodges J . Advances in the early detection of Alzheimer's disease. Nat Med. 2004; 10 Suppl:S34-41. DOI: 10.1038/nrn1433. View

Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso M . Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging. 2004; 25(3):303-10. DOI: 10.1016/S0197-4580(03)00084-8. View

10.

Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K . Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999; 96(6):3228-33. PMC: 15924. DOI: 10.1073/pnas.96.6.3228. View

11.

Selkoe D . Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-91. DOI: 10.1126/science.1074069. View

12.

Yamamoto M, Horiba M, Buescher J, Huang D, Gendelman H, Ransohoff R . Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol. 2005; 166(5):1475-85. PMC: 1606401. DOI: 10.1016/s0002-9440(10)62364-4. View

13.

Braak H, Braak E . Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995; 16(3):271-8; discussion 278-84. DOI: 10.1016/0197-4580(95)00021-6. View

14.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

15.

Stewart W, Kawas C, Corrada M, Metter E . Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997; 48(3):626-32. DOI: 10.1212/wnl.48.3.626. View

16.

Lindberg C, Selenica M, Westlind-Danielsson A, Schultzberg M . Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. J Mol Neurosci. 2005; 27(1):1-12. DOI: 10.1385/JMN:27:1:001. View

17.

Liao Y, Wang B, Cheng H, Kuo L, Wolfe M . Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004; 279(47):49523-32. DOI: 10.1074/jbc.M402034200. View

18.

Perry R, Collins J, Wiener H, Acton R, Go R . The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2002; 22(6):873-83. DOI: 10.1016/s0197-4580(01)00291-3. View

19.

Kordower J, Chu Y, Stebbins G, DeKosky S, Cochran E, Bennett D . Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001; 49(2):202-13. View

20.

Strohmeyer R, Kovelowski C, Mastroeni D, Leonard B, Grover A, Rogers J . Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. J Neuroinflammation. 2005; 2:18. PMC: 1199616. DOI: 10.1186/1742-2094-2-18. View